ANTIPODEAN PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2002-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
3
Active:0
Completed:2
Trial Phases
1 Phases
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (100.0%)A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD)
Phase 2
Terminated
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2011-06-01
- Lead Sponsor
- Antipodean Pharmaceuticals, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT01167088
- Locations
- 🇬🇧
Freeman Hospital, Newcastle-upon-Tyne, United Kingdom
Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C
Phase 2
Completed
- Conditions
- Chronic Hepatitis C
- First Posted Date
- 2007-02-09
- Last Posted Date
- 2008-08-14
- Lead Sponsor
- Antipodean Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00433108
- Locations
- 🇳🇿
New Zealand Liver Unit, Auckland City Hospital, Auckland, New Zealand
🇳🇿Waikato Hospital, Hamilton, New Zealand
A Trial of MitoQ for the Treatment of People With Parkinson's Disease
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2010-07-21
- Lead Sponsor
- Antipodean Pharmaceuticals, Inc.
- Target Recruit Count
- 128
- Registration Number
- NCT00329056
- Locations
- 🇦🇺
Westmead Hospital, Sydney, New South Wales, Australia
🇦🇺The Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
🇦🇺Austin Hospital, Melbourne, Victoria, Australia
News
No news found